News & Updates

Show Multimedia Only

Alcohol intake tied to lower H. pylori infection risk, with caveat

22 Feb 2023

A recent meta-analysis has revealed a decreased risk of Helicobacter pylori infection among alcohol drinkers as compared with nondrinkers, with wine and mixed types of alcohol showing greater infection reduction than beer.

Alcohol intake tied to lower H. pylori infection risk, with caveat

22 Feb 2023

Preserved foods up death risk in esophageal squamous cell carcinoma

21 Feb 2023

A dietary pattern consisting of preserved vegetables, pickled vegetables, and salted meat appears to increase the risk of mortality among patients with esophageal squamous cell carcinoma (ESCC), reveals a recent study. In contrast, fish and shrimp intake may offer a protective benefit.

Preserved foods up death risk in esophageal squamous cell carcinoma

21 Feb 2023

Novel acid-suppressive agent shows therapeutic potential

16 Feb 2023

The novel potassium-competitive acid blocker zastaprazan (JP-1366) appears to have a rapid and potent gastric acid-suppressive effect, with a single oral dose up to 60 mg and multiple oral doses up to 40 mg being safe and well tolerated, according to a study.

Novel acid-suppressive agent shows therapeutic potential

16 Feb 2023

FTD/TPI-bevacizumab combo a new SoC for metastatic CRC?

16 Feb 2023 by

A combination of trifluridine/tipiracil (FTD/TPI) and bevacizumab provided significant survival benefit when used as third-line treatment for refractory metastatic colorectal cancer (CRC) than FTD/TPI alone, findings from the phase III SUNLIGHT study suggest.

FTD/TPI-bevacizumab combo a new SoC for metastatic CRC?

16 Feb 2023

Combo therapy in IBD: Is de-escalation possible after 1 year?

15 Feb 2023 by

Clinicians should consider de-escalating combination therapy with immunomodulators to a monotherapy after 1 year in patients with inflammatory bowel disease (IBD), says an expert at Crohn’s and Colitis Congress 2023.

Combo therapy in IBD: Is de-escalation possible after 1 year?

15 Feb 2023

First-line NALIRIFOX regimen ups survival in metastatic pancreatic cancer

14 Feb 2023 by

The use of liposomal irinotecan in combination with 5-fluorouracil, leucovorin, and oxaliplatin (NALIRIFOX regimen) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) compared with gemcitabine plus nab-paclitaxel (Gem+NabP) in the first-line setting, according to the NAPOLI-3* trial presented at the ASCO GI 2023.

First-line NALIRIFOX regimen ups survival in metastatic pancreatic cancer

14 Feb 2023

Early antibiotics does not prevent infection in hospitalized cirrhosis patients

13 Feb 2023 by

Antibiotics are usually prescribed by physicians to patients hospitalized with decompensated cirrhosis even without an infection diagnosis, according to a UK study. However, this practice has neither reduced the overall risk of hospital-acquired infections (HAI) nor improved survival.